The patients with BCR‐ABL‐positive CML can benefit from target therapy with TKI, however the toxicity and side effects, the drug off‐target risks, the resistance, and the distinction of disease molecular profile are the limiting factors for TKIs.32 Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.